BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30348194)

  • 1. Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.
    Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
    Radiat Oncol; 2018 Oct; 13(1):206. PubMed ID: 30348194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the calculated risk of radiation-induced cancer after photon- and proton-beam based radiosurgery of liver metastases.
    Mondlane G; Gubanski M; Lind PA; Ureba A; Siegbahn A
    Phys Med; 2017 Oct; 42():263-270. PubMed ID: 28366554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential skin morbidity reduction with intensity-modulated proton therapy for breast cancer with nodal involvement.
    Fellin F; Iacco M; D'Avino V; Tommasino F; Farace P; Palma G; Conson M; Giacomelli I; Zucchetti C; Falcinelli L; Amichetti M; Aristei C; Cella L
    Acta Oncol; 2019 Jun; 58(6):934-942. PubMed ID: 30938217
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of single-energy proton pencil beam scanning Bragg peak for intensity-modulated proton therapy FLASH treatment planning in liver-hypofractionated radiation therapy.
    Wei S; Lin H; Shi C; Xiong W; Chen CC; Huang S; Press RH; Hasan S; Chhabra AM; Choi JI; Simone CB; Kang M
    Med Phys; 2022 Oct; 49(10):6560-6574. PubMed ID: 35929404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
    Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
    Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
    Seco J; Gu G; Marcelos T; Kooy H; Willers H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated proton and carbon-ion radiotherapy using a fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.
    Ming X; Mao J; Ma N; Chen J; Wang W; Sheng Y; Wu K
    Phys Med Biol; 2024 Jan; 69(1):. PubMed ID: 38064747
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
    Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
    Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.
    Cozzi L; Comito T; Loi M; Fogliata A; Franzese C; Franceschini D; Clerici E; Reggiori G; Tomatis S; Scorsetti M
    Technol Cancer Res Treat; 2020; 19():1533033820980412. PubMed ID: 33287650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases.
    Mondlane G; Gubanski M; Lind PA; Henry T; Ureba A; Siegbahn A
    Int J Part Ther; 2016; 3(2):277-284. PubMed ID: 31772978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours.
    Petersen JB; Lassen Y; Hansen AT; Muren LP; Grau C; Høyer M
    Acta Oncol; 2011 Aug; 50(6):823-8. PubMed ID: 21767180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy.
    Dell'Oro M; Wilson P; Short M; Hua CH; Merchant TE; Bezak E
    Med Phys; 2022 Jan; 49(1):742-755. PubMed ID: 34796509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients.
    van Dijk LV; Steenbakkers RJ; ten Haken B; van der Laan HP; van 't Veld AA; Langendijk JA; Korevaar EW
    PLoS One; 2016; 11(3):e0152477. PubMed ID: 27030987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric comparison between carbon, proton and photon radiation for renal retroperitoneal soft tissue sarcoma recurrence or metastasis after radical nephrectomy.
    Ming X; Wang W; Shahnazi K; Sun J; Zhang Q; Li P; Hong Z; Sheng Y
    Int J Radiat Biol; 2022; 98(2):183-190. PubMed ID: 34802361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy.
    Toramatsu C; Katoh N; Shimizu S; Nihongi H; Matsuura T; Takao S; Miyamoto N; Suzuki R; Sutherland K; Kinoshita R; Onimaru R; Ishikawa M; Umegaki K; Shirato H
    Radiat Oncol; 2013 Mar; 8():48. PubMed ID: 23497543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
    Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
    Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
    Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
    Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
    Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
    Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
    Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
    Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.